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Abstract
Chronic hepatitis C virus (HCV) infection causes progressive liver fibrosis, cirrhosis, liver 
failure, and hepatocellular carcinoma. Additional to liver damage, HCV infection causes 
a variety of systemic disorders, some of which sometimes bear more severe morbidity 
than the liver disease itself. These extrahepatic manifestations represent a wide spectrum 
of disorders, ranging from the presence of a variety of clinically insignificant autoan-
tibodies to diseases affecting a variety of organ systems. Mixed cryoglobulinemia is a 
common manifestation, and associated vasculitis can affect many organs (kidney, skin, 
and joints). The skin can also be affected by porphyria cutanea tarda and lichen planus. 
Other common extrahepatic manifestations include autoimmune disorders, lymphopro-
liferative disorders, and a number of neurological and neuropsychiatric disorders such 
as fatigue, depression, or cognitive impairment. Insulin resistance, diabetes mellitus, 
accelerated atherosclerosis, and increased cardiovascular disease morbidity and mortal-
ity have also been associated with chronic HCV infection. The existence and severity of 
extrahepatic manifestations do not correlate with the severity of liver disease, and the 
mainstay of treatment is HCV eradication. Patients with systemic manifestations of HCV 
infection should be prioritized for treatment, especially in the era of new interferon-free 
therapies with fewer side effects.
Keywords: chronic hepatitis C infection, extrahepatic manifestations, interferon therapy, 
direct-acting antiviral agents
1. Introduction
Hepatitis C virus (HCV) is a single-stranded RNA virus, a member of the Flaviviridae fam-
ily. As a primarily hepatotropic virus, the main target of infection is hepatocytes, resulting in 
chronic inflammation in about 80% of cases of infection. It is well known that chronic hepatitis 
© 2017 The Author(s). Licensee InTech. Distributed under the terms of the Creative Commons Attribut on-
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C leads to cirrhosis, the terminal stage of liver disease, and hepatocellular carcinoma. It is, 
however, less known that chronic HCV infection leads to a series of systemic disorders and 
diseases that can often leave greater health consequences than the liver disease alone. These 
disorders are commonly called extrahepatic manifestations of chronic hepatitis C and encom-
pass a wide spectrum of conditions, from a clinically insignificant presence of different auto-
antibodies to vasculitis, skin disease, kidney damage, lymphoproliferative disorders, diabetes, 
various neurological and neuropsychiatric changes, and even increased cardiovascular mor-
bidity and mortality [1]. Extrahepatic manifestations in any form may appear in up to 74% of 
patients with chronic HCV infection and may long precede manifest hepatic disease presenting 
with various nonspecific health impairments including malaise, fatigue, nausea, weight loss, 
and musculoskeletal pain [2]. Specific extrahepatic manifestations of chronic hepatitis C can 
be divided according to the affected organ or organ system, pathological mechanism, or the 
strength of available evidence connecting them to chronic hepatitis C infection. Some of the 
extrahepatic manifestations according to organ system and proposed pathological mechanism 
are shown in Tables 1 and 2. The fact that the severity of these disorders does not necessarily 
correlate with the severity of hepatic disease is of great clinical significance because even in 
cases of mildly active chronic hepatitis, a considerable disruption of overall health and quality 









Immunological Autoimmune antibodies: rheumatoid factor, antinuclear, antithyroid, 




Endocrine and exocrine glands Type 2 diabetes mellitus
Sicca syndrome
Musculoskeletal Arthralgia/myalgia





Sensory or sensorimotor polyneuropathy
Mononeuritis multiplex
Cardiovascular Accelerated atherosclerosis
Increased rate of cardiovascular and neurovascular incident and peripheral 
artery disease
Increased mortality from cardiovascular and neurovascular incidents
Table 1. The most common extrahepatic manifestations of chronic hepatitis C according to organ system involvement.
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of life can occur. On the other hand, numerous studies have shown that treatment of chronic 
HCV infection accomplishes the resolution of extrahepatic disease or greatly increases func-
tion of the affected organ and lowers accompanying morbidity and mortality risks. Because of 
this reason, it is accepted and highlighted in current European guidelines, as well as Croatian 
recommendations for treatment of chronic hepatitis C infection, that patients with extrahepatic 
manifestations should be prioritized for treatment, regardless of the activity/severity of their 
liver disease alone [3, 4].
2. Essential mixed cryoglobulinemia
Essential mixed cryoglobulinemia or type II cryoglobulinemia is classified into the group of 
lymphoproliferative disorders in which clonal B lymphocyte expansion leads to immunoglob-
ulin production—polyclonal immunoglobulin (Ig) G class and monoclonal IgM as rheumatoid 
factor (RF)—leading to development of immune complexes that precipitate in the cold and are 
therefore called cryoglobulins. As a consequence of the precipitation of cryoglobulin com-
plexes in small- and middle-sized blood vessels, the occurring complement activation leads to 
endothelial damage and cryoglobulinemic vasculitis [5]. The syndrome can affect blood ves-
sels in different organs and manifest on the skin, large joints, peripheral nerves, or kidneys. 
Cryoglobulins are present in about 50% of patients with chronic hepatitis C infection, but do 
not always cause clinically manifest cryoglobulinemic vasculitis. On the other hand, over 90% 
of patients with essential mixed cryoglobulinemia have chronic hepatitis C infection. The skin 
is commonly affected in cryoglobulinemic syndrome manifesting as palpable purpura as a 
consequence of leukocytoclastic vasculitis [6]. Joint involvement manifests with arthralgias; 
perineural vasculitis is a cause of distal sensory or sensorimotor polyneuropathy, while kid-
ney involvement most often leads to membranoproliferative glomerulonephritis with renal 
function impairment. Diagnosis is based on cryoglobulin presence, elevated RF, and immu-
nofluorescence of complement fixing IgM in affected tissues. It is important to note that many 
studies have shown clinical manifestations of essential mixed cryoglobulinemia to withdraw 
Autoimmune mechanism Proliferative effect Inflammatory/metabolic Other 
mechanism
Autoantibodies Essential mixed 
cryoglobulinemia




Thyroiditis Monoclonal gammopathy Fatigue/malaise
Hepatitis Non-Hodgkin lymphoma Depression
Sicca syndrome Cognitive function damage
Arthralgia/myalgia Cardiovascular disease (coronary 
disease, stroke)
Table 2. Proposed pathogenetic mechanism through which chronic HCV infection leads to extrahepatic manifestations.
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after successful HCV infection treatment and that the presence of mixed cryoglobulinemia is 
associated with a reduced virological response rate [7]. Withdrawal of essential mixed cryo-
globulinemia, with low recurrence levels, has been established earlier with interferon therapy, 
and recently some smaller scale studies showed a very good effect of combined direct-acting 
antiviral therapy (so-called “interferon-free” therapy) in cryoglobulin clearance, renal func-
tion improvement, and proteinuria reduction [8, 9]. The success rates seem to be lower than 
those observed in large registration studies, but the fact the treatment is new and that sample 
sizes were relatively small should be taken into account. It is important to highlight that, in 
some patients, interferon therapy can lead to the worsening of clinical manifestations and that 
in everyday practice optimal antiviral therapy with direct-acting antiviral drugs represents 
the standard of care for patients with clinically mild to moderate cryoglobulinemic vasculitis. 
In severe cases additional therapy modalities such as rituximab, corticosteroids, and plasma-
pheresis may be used before starting antiviral therapy. For refractory forms of cryoglobuline-
mia, cyclophosphamide and other immunosuppressants are sometimes used.
3. B-cell lymphoma and monoclonal gammopathies
Hepatitis C virus is primarily hepatotropic, but it has also been shown to be lymphotropic, 
and a connection between chronic HCV infection and B-cell non-Hodgkin lymphoma (NHL) 
has been established [10, 11]. It is assumed that chronic B lymphocyte stimulation by the HCV 
antigen leads to monoclonal B-cell expansion present in mixed cryoglobulinemia. This seems 
to predispose to NHL occurrence, with studies showing increased risk relative to the general 
population [12]. In a retrospective study comparing untreated HCV-infected patients to those 
treated with interferon, it has been shown that the rates of malignant lymphoma occurrence 
(diffuse large cell lymphoma and follicular lymphoma) were significantly higher in untreated 
patients, as well as in those who did not achieve sustained virologic response (SVR), com-
pared to those who were cured [13]. The importance of chronic HCV infection in lymphoma 
development was additionally confirmed with reports of successful NHL remission after 
HCV eradication. Results with new interferon-free therapies are so far only available as case 
reports but point to lymphoma withdrawal after hepatitis C eradication. It can be expected 
that the wide use of new therapies will show results in larger cohorts of patients.
There are studies suggesting HCV to be a risk factor for monoclonal gammopathies, but 
the results are inconsistent, and a routine screening of patients with chronic hepatitis C for 
monoclonal gammopathies is not recommended. In patients with HCV infection, polyclonal 
or oligoclonal hypergammaglobulinemia (mostly IgG) is present. The gamma globulin level 
often correlates with disease severity on liver biopsy, and its decrease after successful HCV 
treatment has been noted.
4. Kidney impairment
Chronic hepatitis C infection is connected with glomerular disease which is most probably 
a consequence of immune complex deposition in glomerular capillaries. The most common 
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form of kidney disease is membranoproliferative glomerulonephritis, typically connected 
with essential mixed cryoglobulinemia, while membranous nephropathy is less common [14, 
15]. Other non-cryoglobulin-based renal diseases described in HCV-infected patients include 
IgA nephropathy, postinfectious glomerulonephritis, as well as focal and segmental glomeru-
losclerosis. Patients most often present with proteinuria and microhematuria with different 
degrees of renal impairment and with renal biopsy showing glomerular immune complex 
deposition. Acute nephrotic or nephritic syndrome with new onset of arterial hypertension is 
also possible. The Kidney Disease Improving Global Outcomes (KDIGO) guidelines thus rec-
ommend screening for renal impairment at the time of HCV infection diagnosis and then once 
a year by determining serum creatinine and performing urinalysis. All patients with chronic 
kidney disease should also be tested for HCV infection [16]. The existence of renal impair-
ment, especially membranoproliferative glomerulonephritis, is an indication for HCV infec-
tion treatment. Until now the standard of treatment was combined interferon and ribavirin 
(with necessary precaution and kidney function-adjusted dosage), while rituximab, corticoste-
roids, or immunosuppressants are added in patients with severe cryoglobulinemic vasculitis. 
Data about the efficacy of new interferon-free therapies in this indication is only available from 
studies involving a relatively small number of patients, but it can be expected that it could sig-
nificantly change the clinical presentation and improve treatment of this group of patients [8].
5. Skin manifestations
Porphyria cutanea tarda (PCT) is a disease caused by the reduced activity of the hepatic uro-
porphyrinogen decarboxylase (UROD) which leads to accumulation of uroporphyrinogen in 
the blood and urine and is the most common porphyria. PCT can be inherited (autosomal dom-
inant) or acquired (sporadic), and exactly this form was connected with HCV infection in many 
studies. Meta-analysis that included 50 studies and a total of 2167 patients with PCT showed 
that the prevalence of HCV infection was around 50%, while the frequency of PCT in patients 
with chronic HCV infection is about 1–5% [17]. The exact mechanism by which HCV can cause 
or induce PTC is not known, but it is presumed to be mediated through changes in iron metab-
olism. Namely, increased iron saturation, estrogens, and alcohol consumption can provoke or 
induce PCT. Skin changes develop as a consequence of photosensitivity and skin friability and, 
upon sun exposure and/or minor trauma, manifest as erythema and bullae which may turn 
hemorrhagic [18, 19]. In later stages hyperpigmentation, hypopigmentation, hirsutism, and 
sclerodermic changes can appear. In the liver, a spectrum of histological changes can be found, 
including steatosis, mild to severe inflammation, fibrosis, and cirrhosis. Diagnosis of PCT is 
made on the basis of clinical suspicion and is confirmed by measuring increased levels of por-
phyrin in urine and, if available, direct measurement of the UROD enzyme activity. Treatment 
consists of avoiding precipitating factors (sun, alcohol, estrogens) and, if necessary, lowering 
iron overload (venipuncture) as well as treating HCV infection in affected patients. In general, 
treatment of chronic HCV infection leads to the normalization of UROD enzymatic activity, 
levels of liver aminotransferase and urine porphyrin, as well as disappearance of skin changes.
Lichen planus is a chronic inflammatory disease of the skin and mucosa which can affect 
hair and nails and is characterized by pruritic papulae. These most often appear on the skin 
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of extremities, face, scalp, nails, and mucosa of the gastrointestinal and genitourinary tract. 
Lichen planus occurs in various chronic liver diseases, and anti-HCV antibodies can be found 
in 10–40% of patients with lichen planus [20]. It is assumed that the occurrence of lichen pla-
nus is immunologically mediated, but the exact mechanism is unknown. It is also considered 
a premalignant condition and is known to progress to squamous cell carcinoma. The treat-
ment of HCV infection with interferon therapy did not result in regression of lichen planus in 
most studies; on the contrary, there are reports of appearance or exacerbation of lichen pla-
nus during interferon therapy. A recent case series involving seven patients with oral lichen 
planus treated with interferon-free protocols showed an improvement of symptoms without 
adverse events [21].
Leukocytoclastic vasculitis is associated with essential mixed cryoglobulinemia and is a 
consequence of blood vessel involvement. It is clinically characterized by palpable pruritic 
changes and petechiae which usually affect lower extremities and is treated as other manifes-
tations of essential cryoglobulinemia.
Necrolytic acral erythema, a condition characterized by painful, pruritic, and erythematous 
skin lesions of extremities is reported to be strongly associated with chronic HCV infection. 
Zinc supplementation has been associated with improvement of the condition.
Some data supports a possible connection of chronic HCV infection with chronic pruritus, 
while sporadic reports also suggest an association of HCV infection with psoriasis, chronic 
urticaria, pyoderma gangrenosum, erythema nodosum, and erythema multiforme.
6. Ocular manifestations
Mooren’s corneal ulcer represents a rare painful peripheral corneal ulceration, usually with-
out accompanying scleritis. Some studies have made a connection between this rare form of 
corneal ulcer and chronic HCV infection, but the pathogenetic mechanism is not known [22]. 
Chronic HCV infection has been linked to other diseases of the eye such as sicca syndrome, 
keratitis, increased intraocular pressure, and episcleritis, while some disorders such as retinal 
bleeding, vision impairment, as well as rare cases of retinal artery or vein obstruction have 
been described as possible complications of interferon therapy.
7. Thyroid disorders
Thyroid disorders are relatively frequent in patients with chronic hepatitis C, especially in 
women. Antithyroid antibodies are, according to various reports, present in 5–17% (averaging 
at 10%) of patients with HCV infection, while thyroid diseases (mostly hypothyroidism) occur 
less often, in 2–13% of patients [23]. Thyroid function disorders appear even more often during 
interferon therapy, probably as a consequence of autoimmune activity precipitated by immu-
nomodulatory therapy, but can persist even after treatment completion. There is some evi-
dence of a possible HCV infection of thyroid tissue causing a local inflammatory response that 
might trigger the autoimmune process. In any case, determining thyroid hormones as well as 
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anti-thyroglobulin and antithyroid peroxidase antibodies is necessary in all HCV-infected 
patients, especially before and periodically during interferon therapy. Substitution therapy 
with thyroid hormones is used in hypothyroidism treatment. In cases of mild hyperthyroid-
ism, symptomatic therapy is used, while thyrostatic therapy is reserved for more severe cases. 
Interferon therapy should be stopped in cases of severe hyperthyroidism caused by the treat-
ment. It will be interesting to see how the eradication of HCV infection with new drug combina-
tions without interferon affects thyroid function disorders in patients with chronic hepatitis C.
8. Sicca syndrome
The sicca syndrome develops in most patients with Sjögren’s syndrome. Lymphocytic sial-
adenitis resembling Sjögren’s syndrome has been described in patients with chronic HCV 
infection who complain of mouth or eye dryness in 20–30% of cases [15]. There are, however, 
histological (milder, mostly pericapillary lymphocytic infiltration without ductal destruction 
in HCV infection as opposed to periductal infiltration with destruction of excretory ducts in 
classic Sjögren’s syndrome) and clinical differences (less pronounced symptoms, later onset, 
increased levels of serum cryoglobulin and RF, lower complement levels, positive antinu-
clear, and negative Ro/La antibodies). Therefore, it seems that HCV does not cause Sjögren’s 
syndrome but rather symptoms that imitate it [14]. Treatment of chronic HCV infection leads 
to symptom resolution in patients with the sicca syndrome.
9. Other autoimmune manifestations
Various autoantibodies are frequently found in patients with chronic HCV infection. 
Rheumatoid factor (around 60%) is most often present followed by antinuclear antibod-
ies (ANA, around 40%), antithyroid (35%), anticardiolipin (15%), and anti-smooth muscle 
antibodies (ASMA, around 7%), respectively. These antibodies appear in about one-half of 
patients with chronic HCV infection (40–65% according to different studies) but are com-
monly present in low titer and, for the most part, do not seem to affect the clinical course 
of the disease [1]. Antibodies to liver and kidney microsomes (anti-LKM-1) and actin are an 
exception and can be of clinical significance in some HCV-infected patients. These antibodies 
are usually characteristic for autoimmune hepatitis, and it has been noticed that, although 
patients with hepatitis C and anti-LKM-1 antibodies mostly benefit from interferon therapy, 
in some cases an increase in liver function tests can be observed. Some of these patients 
respond well to standard therapy for autoimmune hepatitis which consists of azathioprine 
and corticosteroids. Determining the primary cause of hepatitis in patients with overlapping 
HCV infection and autoantibodies can be very challenging, even though it has been shown 
that anti-LKM-1 antibodies in these patients are directed against different epitopes of cyto-
chrome P450 2D6 compared to patients with autoimmune hepatitis [24]. Even though there 
are no recommendations for routinely determining the presence of these antibodies, if they 
are known to be present, greater caution during interferon therapy is recommended. The role 
of direct-acting antiviral drugs in these patients is yet to be determined.
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Numerous studies have shown a connection between HCV infection and immune thrombo-
cytopenic purpura (ITP) and/or hemolytic anemia, whether as a consequence of the infection 
itself or of interferon therapy. According to the results of one of the largest studies, it seems 
that chronic HCV infection is associated with a higher frequency of ITP in both treated and 
untreated patients, while increased risk of autoimmune hemolytic anemia was only present 
in patients treated with interferon therapy.
10. Musculoskeletal system
Arthralgia is common and reported by 40–80% of patients with chronic hepatitis C [1]. The 
joints are usually symmetrically affected, mostly knees and hands. The afflicted joints are 
painful, without deformities. True arthritis is rare, presenting as rheumatoid like arthritis in 
two-thirds and oligoarthritis in one-third of patients. Rheumatoid factor is present in 70–80% 
of patients with mixed essential cryoglobulinemia, but its presence does not correlate with 
joint affection [15]. Likewise, cyclic citrulline antibodies characteristic for rheumatoid arthritis 
are usually not present. Myalgia is also a common complaint. According to epidemiological 
studies, chronic HCV infection is associated with reduced bone mineral density and increased 
risk of fractures. The mechanism is probably linked to chronic inflammation and liver disease. 
Hepatitis C-associated osteosclerosis, mostly reported in patients with a history of intrave-
nous drug abuse, is an uncommon disorder characterized by an increase in bone mass during 
adulthood. The increased bone turnover in periosteal, endosteal, and trabecular bone leads 
to the thickening of the skeleton and may respond to bisphosphonate or calcitonin therapy.
11. Neurological manifestations
Neurological manifestations of HCV infection can vary from central nervous system (CNS) 
involvement to peripheral neuropathy including sensorimotor neuropathy and mononeuritis 
multiplex. Evidence of CNS involvement includes the demonstration of HCV RNA in brain 
tissue and cerebrospinal fluid suggesting active replication and as well as a possible associa-
tion of HCV infection and small vessel cerebrovascular disease [25–27]. The most common 
form of nerve involvement is distal sensory or sensorimotor polyneuropathy, which clinically 
presents with painful, asymmetric paresthesia, while multiple mononeuropathy occurs rarely 
[15]. These changes are a consequence of vasculitis, sometimes associated with cryoglobuline-
mia, involving vasa nervorum.
In a recently published study, chronic HCV infection has been linked to Parkinson’s disease [28].
12. Neuropsychiatric disorders
Neurocognitive damages can manifest with a wide array of neuropsychiatric conditions, such 
as tiredness, depression, and lack of concentration and working memory, of which patients 
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with chronic HCV infection often complain. These disorders are often seen and intertwined 
with other associated additions, such as chronic liver disease, cirrhosis, the use of drugs, 
and others. Some studies have managed to show that these neurocognitive damages are a 
consequence of the HCV infection itself, regardless of comorbidities [29]. Functional imag-
ing methods have shown metabolic changes in brains of chronic hepatitis C patients, with 
improvement of cognitive function and brain metabolism observed after treating the HCV 
infection [30]. Some of these disorders such as depression and fatigue are important because 
they can exacerbate under interferon therapy. This is why it is important to perform mental 
status evaluation at the beginning and during this therapy, so as to be able to timely act with 
suitable psychiatric support, antidepressants, and anxiolytics. Fatigue, depression, and cogni-
tive damage significantly impair functional ability (at work and at home) and impact the qual-
ity of life of patients with chronic HCV infection, while the eradication of the virus positively 
correlates with an improvement in quality of life.
13. Metabolic manifestations: diabetes mellitus and insulin resistance
Disturbed glucose metabolism, onset of insulin resistance (IR), and type 2 diabetes mellitus 
(T2DM) are often associated with chronic HCV infection. A meta-analysis of 34 studies con-
firmed a positive correlation between HCV infection and risk of T2DM, which is 1.7 times 
greater than the general population and notably increased compared to chronic hepatitis 
B patients [31]. It appears that the risk of T2DM in patients with chronic HCV infection is 
increased in patients with risk factors such as older age, obesity, advanced liver fibrosis, and 
a family history of diabetes [32]. Likewise, results of multiple studies have shown that suc-
cessful eradication of HCV infection decreases IR and that the risk of T2DM is decreased in 
patients who achieved SVR [33]. Multiple studies have confirmed an association between the 
HCV infection and IR development that can be present without manifest T2DM. Experimental 
studies have shown that HCV causes significant changes in the lipid and glucose metabolism 
and that it leads to IR in the liver and peripheral tissue through direct (immediate influence of 
HCV proteins on intracellular insulin signal pathways) and indirect (the influence of TNF-α 
and other cytokines on the development of peripheral IR) mechanisms. Insulin resistance 
causes a series of changes in lipid and lipoprotein metabolism and leads to the development 
of liver steatosis [34]. Clinical implications of HCV-induced IR, besides T2DM development, 
include a worse response to interferon therapy, accelerated fibrosis and development of cir-
rhosis, increased risk of hepatocellular carcinoma, as well as increased cardiovascular mor-
bidity and mortality [35].
14. Cardiovascular disease
Chronic HCV infection has been associated with accelerated atherosclerosis [36]. Risk of early 
carotid artery atherosclerosis (determined by intima-media thickness measurement) was 
four times greater in HCV patients than noninfected patients [14, 37]. In several cohorts of 
HCV-positive patients, increased cardiovascular mortality (1.5–25 times) as well as a higher 
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incidence of cerebrovascular and acute coronary syndromes was noted [38]. Besides coronary 
and cerebrovascular disease, an increased rate of peripheral arterial disease in patients with 
a chronic HCV infection has been described. Rates of acute coronary syndrome and ischemic 
stroke were significantly reduced in patients treated with peginterferon and ribavirin com-
pared to untreated patients [39]. Although this association was found in studies originating 
from Far East countries, Western European and American studies, as well as a recent meta-
analysis, have not established a clear correlation of HCV infection and increased cardiovas-
cular and cerebrovascular risk [40, 41]. Likewise, the pathogenetic mechanism through which 
HCV leads to accelerated atherosclerosis has not been fully elucidated. There is evidence of 
HCV RNA presence in carotid plaques and endothelial cells in the brain, and it is possible 
that local infection leads to tissue damage, but atherosclerosis is more probably a conse-
quence of the aforementioned IR, metabolism disturbance, and proinflammatory cytokine 
action. Many unsolved questions leave space for further research, and the arrival of new 
therapies opens new possibilities in treating patients with an expected decrease in cardiovas-
cular morbidity and mortality.
15. Other HCV infection-associated diseases
Pulmonary fibrosis is a disease characterized by interstitial inflammation with focal fibroblast 
proliferation and collagen deposits leading to fibrosis, which clinically commonly manifests 
as dyspnea on exertion and nonproductive cough. The disease pathogenesis is unknown, and 
several studies have found a connection between pulmonary fibrosis and chronic HCV infec-
tion. A higher prevalence of pulmonary fibrosis was seen in HCV-infected patients than con-
trol groups, and vice versa, a group of patients with diagnosed idiopathic pulmonary fibrosis 
had an increased anti-HCV positivity rate (25%) [38].
Myasthenia gravis was associated with HCV infection in case reports only, and a clear link 
has not been established. Cases of this disease developing during interferon treatment have 
been described, but it is assumed that these cases were in fact exacerbations of subclinical 
disease precipitated by immunomodulatory therapy.
16. Conclusion
Chronic hepatitis C infection (HCV) is a systemic disease which, besides the liver as its pri-
mary target, affects a number of other organs and organ systems. So far more than 30 differ-
ent conditions have been associated with chronic HCV infection. In general, the appearance 
of extrahepatic manifestations of HCV infection is unpredictable, that is, independent of the 
stage of the liver disease. A clear association with chronic hepatitis C has been established for 
many of these conditions, while, for some diseases, good-quality evidence linking them to 
HCV infection is still missing.
Considering the appearance of new direct-acting antiviral therapies that offer an excellent 
prospect for cure of infected patients, although at a relatively high expense, the practice in 
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Croatia, as well as in many economically limited countries, is to set treatment priorities, so as 
to sooner treat the patients that need it most. Taking this into regard, patients with established 
extrahepatic manifestations of HCV infection have priority in receiving treatment, regardless 
of the stage of their liver disease, as stated in the latest guidelines.
For example, patients with essential mixed cryoglobulinemia and its skin (leukocytoclastic 
vasculitis), kidney (membranoproliferative glomerulonephritis or membranous nephropathy, 
renal failure), or nerve (neuropathy) manifestations, as well as patients with non-Hodgkin 
lymphoma, porphyria cutanea tarda, and some other more rare autoimmune disease mani-
festations, will benefit from treatment not only by eradicating HCV but also in treating the 
extrahepatic manifestation and its sometimes very debilitating symptoms.
It can be expected, and recent studies show promising results, that new therapies with-
out interferon which greatly improve therapeutic success with fewer adverse effects 
will prove especially beneficial in patients with immunologically mediated extrahepatic 
manifestations.
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